NASDAQ:MEIP MEI Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MEI Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.08 -0.18 (-5.52 %) (As of 09/23/2020 12:00 AM ET) Add Compare Share Today's Range$3.06Now: $3.08▼$3.2950-Day Range$2.46MA: $2.83▼$3.5452-Week Range$0.72Now: $3.08▼$4.46Volume807,556 shsAverage Volume1.50 million shsMarket Capitalization$346.57 millionP/E RatioN/ADividend YieldN/ABeta1.87 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media MEI Pharma, Inc., a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. The company has a license, development, and commercialization agreement with Helsinn Healthcare SA for the development, manufacture, and commercialization of Pracinostat; and license agreement with Presage Biosciences, Inc. to develop, manufacture, and commercialize Voruciclib, a clinical-stage, oral, and selective cyclin-dependent kinase inhibitor; and related compounds. It also has a clinical collaboration agreement with BeiGene, Ltd. to evaluate the safety and efficacy of ME-401 in combination with BeiGene's zanubrutinib, an investigational BTK inhibitor for the treatment of patients with B-cell malignancies. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.4 Analyst's Opinion Consensus RatingMEI Pharma has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.60, MEI Pharma has a forecasted upside of 244.2% from its current price of $3.08.Amount of Analyst CoverageMEI Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesMEI Pharma has received 347 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMEI Pharma has received 275 “underperform” votes. (Add your “underperform” vote.)Community SentimentMEI Pharma has received 55.79% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote “Outperform” if you believe MEIP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMEI Pharma does not currently pay a dividend.Dividend GrowthMEI Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MEI Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.77% of the stock of MEI Pharma is held by insiders.Percentage Held by Institutions59.32% of the stock of MEI Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for MEI Pharma are expected to grow in the coming year, from ($0.47) to ($0.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MEI Pharma is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MEI Pharma is -6.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMEI Pharma has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.57 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MEIP Previous SymbolNASDAQ:MSHL CUSIPN/A CIK1262104 Webwww.meipharma.com Phone858-369-7100Debt Debt-to-Equity RatioN/A Current Ratio8.95 Quick Ratio8.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$28.91 million Price / Sales11.99 Cash FlowN/A Price / Cash FlowN/A Book Value$0.74 per share Price / Book4.16Profitability EPS (Most Recent Fiscal Year)($0.26) Net Income$-46,010,000.00 Net Margins-159.15% Return on Equity-33.39% Return on Assets-19.19%Miscellaneous Employees32 Outstanding Shares112,522,000Market Cap$346.57 million Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $3.08 -0.18 (-5.52 %) (As of 09/23/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MEIP News and Ratings via Email Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter. MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions How has MEI Pharma's stock been impacted by COVID-19? MEI Pharma's stock was trading at $1.55 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MEIP stock has increased by 98.7% and is now trading at $3.08. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of MEI Pharma? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MEI Pharma. When is MEI Pharma's next earnings date? MEI Pharma is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for MEI Pharma. How were MEI Pharma's earnings last quarter? MEI Pharma Inc (NASDAQ:MEIP) announced its earnings results on Thursday, May, 7th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.09. The business earned $1.24 million during the quarter, compared to the consensus estimate of $1.28 million. MEI Pharma had a negative return on equity of 33.39% and a negative net margin of 159.15%. View MEI Pharma's earnings history. What price target have analysts set for MEIP? 5 equities research analysts have issued 12 month price targets for MEI Pharma's stock. Their forecasts range from $9.00 to $13.00. On average, they expect MEI Pharma's share price to reach $10.60 in the next year. This suggests a possible upside of 244.2% from the stock's current price. View analysts' price targets for MEI Pharma. Who are some of MEI Pharma's key competitors? Some companies that are related to MEI Pharma include Heron Therapeutics (HRTX), MacroGenics (MGNX), Mersana Therapeutics (MRSN), Intercept Pharmaceuticals (ICPT), Generation Bio (GBIO), Rocket Pharmaceuticals (RCKT), INDIVIOR PLC/S (INVVY), Epizyme (EPZM), Trillium Therapeutics (TRIL), Amneal Pharmaceuticals (AMRX), Repare Therapeutics (RPTX), Arcus Biosciences (RCUS), Passage Bio (ZNTL), Rhythm Pharmaceuticals (RYTM) and Stoke Therapeutics (STOK). View all competitors. What other stocks do shareholders of MEI Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Idera Pharmaceuticals (IDRA), Opko Health (OPK), Sorrento Therapeutics (SRNE) and TherapeuticsMD (TXMD). Who are MEI Pharma's key executives? MEI Pharma's management team includes the following people: Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)Mr. David A. Walsey, VP of IR & Corp. Communications What is MEI Pharma's stock symbol? MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP." Who are MEI Pharma's major shareholders? MEI Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (4.54%), Wasatch Advisors Inc. (4.10%), BVF Inc. IL (3.90%), Opaleye Management Inc. (1.47%), Nuveen Asset Management LLC (1.27%) and Point72 Asset Management L.P. (1.09%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds. View institutional ownership trends for MEI Pharma. Which major investors are selling MEI Pharma stock? MEIP stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Wasatch Advisors Inc., Driehaus Capital Management LLC, ClariVest Asset Management LLC, WINTON GROUP Ltd, UBS Group AG, and Jane Street Group LLC. View insider buying and selling activity for MEI Pharma. Which major investors are buying MEI Pharma stock? MEIP stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Point72 Asset Management L.P., Nuveen Asset Management LLC, Artal Group S.A., Marshall Wace North America L.P., Marshall Wace LLP, Assenagon Asset Management S.A., and EAM Investors LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, and Thomas C Reynolds. View insider buying and selling activity for MEI Pharma. How do I buy shares of MEI Pharma? Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is MEI Pharma's stock price today? One share of MEIP stock can currently be purchased for approximately $3.08. How big of a company is MEI Pharma? MEI Pharma has a market capitalization of $346.57 million and generates $28.91 million in revenue each year. The company earns $-46,010,000.00 in net income (profit) each year or ($0.26) on an earnings per share basis. MEI Pharma employs 32 workers across the globe. What is MEI Pharma's official website? The official website for MEI Pharma is www.meipharma.com. How can I contact MEI Pharma? MEI Pharma's mailing address is 11455 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
